Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
You got the wrong guy. I only followed up on the guy who mentioned 360M shares. I was curious about the weighted avg. stock options 1: $8,771.60.
Get back to me on that and I would appreciate it.
Purpura’s porn ‘stache is worth $360,000. That’s as legit as they come.
Does anyone know if the exec team has the garden variety common stock/stock options, or those that happen to have a weighted average exercise price of $8,771.60 per share?
By the by, 100% chance I would believe it if someone told me Sam wrote these paragraphs.
The table above excludes the following potentially dilutive securities as of January 31, 2018:
• 129 shares issuable upon the exercise of stock options at a weighted average exercise price of $8,771.60 per share;
• 7.0 million shares issuable upon the exercise of outstanding warrants at a weighted average exercise price of $3.14 per share;
• 76 shares reserved for future issuance under our 2009 Equity Incentive Plan, as amended;
• 500,000,000 Warrant Shares underlying the Series D warrants to be issued hereunder; and
• 285 unvested restricted shares.
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
The following tables contain information regarding the beneficial ownership of our common stock as of January 31, 2018, held by: (i) each of our directors; (ii) each of our named executive officers in the Summary Compensation Table; (iii) all of our directors and executive officers as a group; and (iv) each person or group known by us to own beneficially more than 5% of the outstanding common stock. We are not aware of any 5% or more holders of our Common Stock as of January 31, 2018 except as set forth below. The information set forth in the table below excludes shares issuable upon exercise of our outstanding warrants held by certain investors that are presently exercisable, subject to limitations on exercisability for more than 4.9% or 9.9% of our outstanding shares of common stock, depending upon the particular investor. Except as indicated in the footnotes below, the address of the persons or groups named below is c/o Delcath Systems, Inc., 1633 Broadway, Suite 22C, New York, New York 10019.
Directors and Officers
Shares
Beneficially
Owned (1)
Name of Beneficial Owner: Number Percent
Named Executive Officers and Directors:
Jennifer K. Simpson, Ph.D.(2) 132 *
John Purpura, M.S.(3) 106 *
Barbra C. Keck, M.B.A.(4) 73 *
Simon Pedder, PhD.(5) — *
Roger G. Stoll, Ph.D.(6) 9 *
William D. Rueckert(7) 17 *
Marco Taglietti, M.D.(8) 49 *
All directors and executive officers as a group (7 people)(9): *
* Less than 1%
(1) Except as indicated in these footnotes: (i) the persons named in this table have sole voting and investment power with respect to all shares of common stock beneficially owned; (ii) the number of shares beneficially owned by each person as of January 31, 2018, includes any vested and unvested shares of restricted stock and any shares of common stock that such person or group has the right to acquire within 60 days of January 31, 2018, upon the exercise of stock options; and (iii) for each person or group included in the table, percentage ownership is calculated by dividing the number of shares beneficially owned by such person or group by the sum of the 182,981,824 shares of common stock outstanding on January 31, 2018, plus the number of shares of common stock that such person or group has the right to acquire within 60 days of January 31, 2018.
(2) Includes 13 shares of common stock, which Dr. Simpson has the right to acquire upon exercise of outstanding options exercisable within 60 days of January 31, 2018.
(3) Includes 7 shares of common stock, which Mr. Purpura has the right to acquire upon exercise of outstanding options exercisable within 60 days of January 31, 2018.
(4) Includes 5 shares of common stock, which Ms. Keck has the right to acquire upon exercise of outstanding options exercisable within 60 days of January 31, 2018, and 4 shares held in a joint account with her spouse.
(5) Dr. Pedder has not yet received an equity grant.
(6) Includes 5 shares of common stock, which Dr. Stoll has the right to acquire upon exercise of outstanding options exercisable within 60 days of January 31, 2018
(7) Includes 10 shares of common stock, which Mr. Rueckert has the right to acquire upon exercise of outstanding options exercisable within 60 days of January 31, 2018.
(8) Includes 10 shares of common stock, which Dr. Taglietti has the right to acquire upon exercise of outstanding options exercisable within 60 days of January 31, 2018.
(9) Includes 55 shares of common stock, which certain directors and executive officers have the right to acquire upon exercise of outstanding options exercisable within 60 days of January 31, 2018.
You should think about a part time gig writing soap operas.
HERR TROMPETE:
In nicht allzu ferner Zukunft werden viele Kurzfilme Admiral Akbar'd sein. Er wusste nicht, dass es eine Falle war; Er konnte nicht glauben, dass es eine Falle war.
Trotzdem war es eine Falle. Die Sterne sind langsam, aber sicher ausgerichtet. Ich hoffe, dass Sie in der Lage sind, etwas Geld zu verdienen, wenn dies geschieht, damit Sie eines Tages im DCTH iHub-Forum glücklich sein können.
Das ist alles.
P.S. TRAAAA LAAAAA LAAAAAAAAAAAAAAAAAAAAAA!!!
You seem pretty confident about the RS.
Be sure to keep watch for the Magic Man.
Abracadabra, bro.
I don’t even know what that means but I like the sound of it.
Can someone please vanquish the 500K by OTCX. I shot my wad at the open. That is all.
i'D LOVE TO SEE SOMEONE BEAT OTCX'S 500K SHARES LIKE A BABY SEAL RIGHT ABOUT NOW!
TRAAAA LAAA LAAAAAAA
LET HER RUN, PONY BOY!!!
TICK TOCK SHORTIES.
DID I JUST SEE A LITTLE BABY GAP ON THE BID?
TRAAA LAAAAA LAAAAAAAAAAAAA!!!
TRAAAA LAAAAAA LAAAAAAAAAAAAAAAAAAAAAAAAAAA!!!
TODAY= REVERSAL DAY +1
It is curious that you trigger only to a few select topics.
Thanks for sharing. There is interest. Good to see.
Okay, now I am finally off. Good day all.
Biggie Smalls in the House!
I’ve had insomnia the past two days as well.
But seeing green today will make it all worth while!
Mark this post: reversal began yesterday.
The funny thing? HULK was the first to spot it.
Off to work.
GLTYA. I hope everyone has a profitable day!
Shhh. I need my beauty sleep to stave off all the wrinkles you and Trompete cause.
Got it. Good lord, I need some rest. Next few days should be interesting.
Buffalo Soldier, thought big buyout was coming? Want changed? Went from BK to buyout, to...
Still holding a million shares at $.04?
Second reading of Right To Try in the Senate on Thursday, April 5th.
Who is your network, and do you have proof? Let’s bust some heads of you do.
Why is it that the SEC only looks at Fail to Deliver Reports as the leading indicator of naked shorts?
I’ve heard people say the otc website you cite doesn’t contain accurate information.
Not being a smart Alek, just genuinely curious.
How can retail be driven out completely yet you are waiting for the fireworks?
What did I miss?
Bunch of bums.
Moving north, baby. Today’s action was organic. Wait until volume and KAPOW.
That's it?
Market Cap $3.7M.
SMH.
Bout to take out those .0093 baby!
Thanks!
Lol. Love it.
Ok; thanks. Yeah a site owner can install Google analytics and can get a wealth of info about traffic to the site.
Question:
I am curious, would you be willing to share your Google analytics on the Delcath site? I’d like to see how traffic looks.
Memo to Turnip. What would happen if RS IS ANNOUNCED, along with news that would make it possible to maintain or grow PPS post-RS, with DCTH openly stating its intention to uplist to NASDAQ?
As plausible a scenario as the one you just proffered.
TICK TOCK!
HAHA HULK LAUGH AT ALL SHORTS RUNNING TO MESSAGE BOARD. WHEN THIS GO POP, BARCHART WILL SAY STRONG SELL ON POSTER WHO SPELLS NAME LIKE PRINCE OR MC HAMMER.
HULK SAY POWER HOUR COMING. SHORTS COVER OR BURN, IN HULK OPINION
REVERSAL START TODAY.
HULK SAY RSI38 GO PLAY WITH PONY.
HULK LAUGH AT YOU. PUNY LITTLE PONY WORTH $.0003.
HULK SEE GREEN.
HULK LIKE GREEN.
HULK NEED GREEN.
HULK SAY REVERSAL HERE.
HULK SAY BAD TIME TO BE SHORT.
HULK SAY TICK TOCK.
HULK SEE PRESIDENT LINCOLN TODAY.
HULK LOVE GREEEEEEEEEEEEEEEEEEEEEEEEN!!!
Delcath’s PHP Therapy to be Featured in Video Training Session at European Conference of Interventional Oncology
NEW YORK, April 03, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB:DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces that Dr. Brian Steadman, Interventional Oncologist at the Southampton University Hospital will present a video training session at the Annual Meeting of the European Conference of Interventional Oncology (ECIO). Dr. Steadman will present an overview of the Percutaneous Hepatic Perfusion (PHP) procedure and potential indications of PHP Therapy, as well as review recent research. The session will be held Tuesday, April 24, 2018 at 3pm local time.
http://www.globenewswire.com/news-release/2018/04/03/1459109/0/en/Delcath-s-PHP-Therapy-to-be-Featured-in-Video-Training-Session-at-European-Conference-of-Interventional-Oncology.html
And from the 10K:
United Kingdom
In May 2014, NICE, a non-departmental public body that provides guidance and advice to improve health and social care in the UK, completed a clinical review of CHEMOSAT. The NICE review indicated that as the current body of evidence on the safety and efficacy of PHP with CHEMOSAT for primary or metastatic liver cancer is limited, the procedure should be performed within the context of research by clinicians with specific training in its use and techniques. Delcath expects to consult again with the Interventional Procedures Advisory Committee at the National Institute for Clinical Excellence (NICE) in England, to provide recent clinical evidence with a view to moving existing Interventional Procedural Guidance from research to specialist status. This would enable greater scope for commercialization because it would allow more use by NHS clinicians of the therapy. It might also pave the way for a full Medical Technology Assessment as a way towards longer term reimbursement with the NHS.
DCTH is moving forward. PPS will follow, IMO.
Hahaha! Fear not, Turnip or Salacious B. Crumb will gap fill!
Coal has plenty of value too!